WO2002000717A3 - Novel co-stimulatory molecules - Google Patents

Novel co-stimulatory molecules Download PDF

Info

Publication number
WO2002000717A3
WO2002000717A3 PCT/US2001/019973 US0119973W WO0200717A3 WO 2002000717 A3 WO2002000717 A3 WO 2002000717A3 US 0119973 W US0119973 W US 0119973W WO 0200717 A3 WO0200717 A3 WO 0200717A3
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptides
ctla
ability
human
novel
Prior art date
Application number
PCT/US2001/019973
Other languages
French (fr)
Other versions
WO2002000717A9 (en
WO2002000717A2 (en
Inventor
Juha Punnonen
Alexandra L L Lazetic
Steven R Leong
Chia-Chun Jean Chang
Doris Apt
Claes Gustafsson
Original Assignee
Maxygen Inc
Juha Punnonen
Alexandra L L Lazetic
Steven R Leong
Chia-Chun Jean Chang
Doris Apt
Claes Gustafsson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP01952193A priority Critical patent/EP1360290A2/en
Priority to AU2001272978A priority patent/AU2001272978A1/en
Priority to CA002411828A priority patent/CA2411828A1/en
Priority to JP2002505839A priority patent/JP2004513878A/en
Application filed by Maxygen Inc, Juha Punnonen, Alexandra L L Lazetic, Steven R Leong, Chia-Chun Jean Chang, Doris Apt, Claes Gustafsson filed Critical Maxygen Inc
Priority to US10/032,214 priority patent/US7183376B2/en
Publication of WO2002000717A2 publication Critical patent/WO2002000717A2/en
Priority to PCT/US2002/019898 priority patent/WO2004029197A2/en
Priority to EP02807658A priority patent/EP1497426A2/en
Priority to AU2002368044A priority patent/AU2002368044A1/en
Priority to US10/479,901 priority patent/US20050154189A1/en
Publication of WO2002000717A9 publication Critical patent/WO2002000717A9/en
Publication of WO2002000717A3 publication Critical patent/WO2002000717A3/en
Priority to US11/645,361 priority patent/US20100261660A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The invention provides polynucleotides and polypeptides encoded therefrom having advantageous properties, including an ability of the polypeptides to preferentially bind a CD28 or CTLA-4 receptor at a level greater or less than the ability of human B7-1 to bind CD28 or CTLA-4, or to induce or inhibit altered level of T cell proliferation response greater compared to that generated by human B7-1. The polypeptides and polynucleotides of the invention are useful in therapeutic and prophylactic treatment methods, gene therapy applications, and vaccines.
PCT/US2001/019973 2000-06-23 2001-06-22 Novel co-stimulatory molecules WO2002000717A2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
EP01952193A EP1360290A2 (en) 2000-06-23 2001-06-22 Co-stimulatory molecules
AU2001272978A AU2001272978A1 (en) 2000-06-23 2001-06-22 Novel co-stimulatory molecules
CA002411828A CA2411828A1 (en) 2000-06-23 2001-06-22 Novel co-stimulatory molecules
JP2002505839A JP2004513878A (en) 2000-06-23 2001-06-22 Novel costimulatory molecules
US10/032,214 US7183376B2 (en) 2000-06-23 2001-12-20 Variant B7 co-stimulatory molecules
PCT/US2002/019898 WO2004029197A2 (en) 2001-06-22 2002-06-21 Co-stimulatory molecules
US10/479,901 US20050154189A1 (en) 2000-06-23 2002-06-21 Novel co-stimulatory molecules
EP02807658A EP1497426A2 (en) 2001-06-22 2002-06-21 Co-stimulatory molecules
AU2002368044A AU2002368044A1 (en) 2001-06-22 2002-06-21 Co-stimulatory molecules
US11/645,361 US20100261660A1 (en) 2000-06-23 2006-12-22 Novel co-stimulatory molecules

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US21394600P 2000-06-23 2000-06-23
US60/213,946 2000-06-23
US24124500P 2000-10-17 2000-10-17
US60/241,245 2000-10-17

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US09/888,324 Continuation-In-Part US7094875B2 (en) 2000-06-23 2001-06-22 Co-stimulatory polypeptides
US10/032,214 Continuation-In-Part US7183376B2 (en) 2000-06-23 2001-12-20 Variant B7 co-stimulatory molecules

Publications (3)

Publication Number Publication Date
WO2002000717A2 WO2002000717A2 (en) 2002-01-03
WO2002000717A9 WO2002000717A9 (en) 2003-02-06
WO2002000717A3 true WO2002000717A3 (en) 2003-08-21

Family

ID=26908547

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/019973 WO2002000717A2 (en) 2000-06-23 2001-06-22 Novel co-stimulatory molecules

Country Status (6)

Country Link
US (2) US7094875B2 (en)
EP (1) EP1360290A2 (en)
JP (1) JP2004513878A (en)
AU (1) AU2001272978A1 (en)
CA (1) CA2411828A1 (en)
WO (1) WO2002000717A2 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002000717A2 (en) * 2000-06-23 2002-01-03 Maxygen, Inc. Novel co-stimulatory molecules
US20050154189A1 (en) * 2000-06-23 2005-07-14 Maxygen Inc Novel co-stimulatory molecules
WO2004029197A2 (en) * 2001-06-22 2004-04-08 Maxygen, Inc. Co-stimulatory molecules
CA2484743A1 (en) * 2002-05-08 2003-11-20 Northwest Biotherapeutics, Inc. Quality assays for antigen presenting cells
AR058568A1 (en) 2005-12-20 2008-02-13 Bristol Myers Squibb Co METHODS TO PRODUCE A COMPOSITION WITH CTLA4-IG MOLECULES FROM A CROP MEANS
PL2253644T3 (en) 2005-12-20 2014-04-30 Bristol Myers Squibb Co Compositions and methods for producing a composition
WO2009033050A1 (en) * 2007-09-07 2009-03-12 University Of Pittsburgh-Of The Commonwealth Sys Tem Of Higher Education Diagnostic and therapeutic uses of augmenter of liver regeneration in inflammatory conditions
PL2612868T3 (en) * 2007-11-01 2018-12-31 Astellas Pharma Inc. Immunosuppressive polypeptides and nucleic acids
US20140148390A1 (en) * 2011-07-08 2014-05-29 Bayer Intellectual Property Gmbh Fusion proteins releasing relaxin and uses thereof
SI2867251T1 (en) * 2012-06-29 2019-12-31 Bristol-Myers Squibb Company Methods for reducing glycoprotein aggregation
MX2015017959A (en) 2013-06-24 2018-03-01 Neximmune Inc Compositions and methods for immunotherapy.
ES2897707T3 (en) 2014-12-24 2022-03-02 Neximmune Inc Nanoparticle compositions and methods for immunotherapy
US10689449B2 (en) 2015-01-20 2020-06-23 Igm Biosciences, Inc. Multimeric death domain-containing receptor-5 (DR5) antibodies and uses thereof
CN107969128A (en) 2015-04-17 2018-04-27 高山免疫科学股份有限公司 Immune modulator with adjustable affinity
JP2018534245A (en) * 2015-09-14 2018-11-22 アルパイン イミューン サイエンシズ インコーポレイテッド Tunable variant immunoglobulin superfamily domains and modified cell therapy
KR20190006495A (en) 2016-04-15 2019-01-18 알파인 이뮨 사이언시즈, 인코포레이티드 CD80 variant immunoregulatory proteins and uses thereof
WO2018022945A1 (en) 2016-07-28 2018-02-01 Alpine Immune Sciences, Inc. Cd112 variant immunomodulatory proteins and uses thereof
US11471488B2 (en) 2016-07-28 2022-10-18 Alpine Immune Sciences, Inc. CD155 variant immunomodulatory proteins and uses thereof
US11732022B2 (en) 2017-03-16 2023-08-22 Alpine Immune Sciences, Inc. PD-L2 variant immunomodulatory proteins and uses thereof
AU2018235838B2 (en) 2017-03-16 2023-12-14 Alpine Immune Sciences, Inc. CD80 variant immunomodulatory proteins and uses thereof
EP3694870A1 (en) 2017-10-10 2020-08-19 Alpine Immune Sciences, Inc. Ctla-4 variant immunomodulatory proteins and uses thereof
EA202090974A1 (en) 2017-10-18 2020-08-05 Элпайн Иммьюн Сайенсиз, Инк. VARIANT IMMUNOMODULATING PROTEINS OF ICOS LIGAND AND ACCOMPANYING COMPOSITIONS AND METHODS
CN113795502A (en) * 2019-04-26 2021-12-14 轩竹生物科技有限公司 CD80 variant protein and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999057271A2 (en) * 1998-05-01 1999-11-11 The Texas A&M University System Feline cd80, feline cd86, feline cd28, and feline ctla-4 nucleic acid and polypeptides

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5866363A (en) 1985-08-28 1999-02-02 Pieczenik; George Method and means for sorting and identifying biological information
US5824469A (en) 1986-07-17 1998-10-20 University Of Washington Method for producing novel DNA sequences with biological activity
US6641809B1 (en) 1990-03-26 2003-11-04 Bristol-Myers Squibb Company Method of regulating cellular processes mediated by B7 and CD28
US5475099A (en) 1990-08-15 1995-12-12 Calgene Inc. Plant fatty acid synthases
US6071716A (en) 1990-10-01 2000-06-06 Dana-Farber Cancer Institute DNA encoding, B7, a new member of the IG superfamily with unique expression on activated and neoplastic B cells
US5512463A (en) 1991-04-26 1996-04-30 Eli Lilly And Company Enzymatic inverse polymerase chain reaction library mutagenesis
US5718883A (en) 1993-04-14 1998-02-17 The United States Of America As Represented By The Secretary Of The Navy Transgenic animal model for autoimmune diseases
KR960701988A (en) 1993-04-20 1996-03-28 윌리엄 에스. 로빈슨 METHODS AND MATERIALS FOR TREATMENT OF INDIVIDUALS INFECTED WITH INTRACELLULAR IN-FECTIOUS AGENTS
EP0711345A1 (en) 1993-07-26 1996-05-15 Dana Farber Cancer Institute B7-2: ctl a4/cd 28 counter receptor
US5942607A (en) 1993-07-26 1999-08-24 Dana-Farber Cancer Institute B7-2: a CTLA4/CD28 ligand
US6084067A (en) 1993-07-26 2000-07-04 Dana-Farber Cancer Institute CTLA4/CD28 ligands and uses therefor
US5858776A (en) 1993-11-03 1999-01-12 Repligen Corporation Tumor cells with increased immunogenicity and uses therefor
US6130316A (en) 1993-07-26 2000-10-10 Dana Farber Cancer Institute Fusion proteins of novel CTLA4/CD28 ligands and uses therefore
US5861310A (en) 1993-11-03 1999-01-19 Dana-Farber Cancer Institute Tumor cells modified to express B7-2 with increased immunogenicity and uses therefor
US6117679A (en) 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6335160B1 (en) 1995-02-17 2002-01-01 Maxygen, Inc. Methods and compositions for polypeptide engineering
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5834252A (en) 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5928905A (en) 1995-04-18 1999-07-27 Glaxo Group Limited End-complementary polymerase reaction
US6165793A (en) 1996-03-25 2000-12-26 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6218510B1 (en) 1994-03-02 2001-04-17 Brigham & Woman's Hospital B7-1 and B7-2 polypeptides
US6045802A (en) 1994-10-03 2000-04-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule
US5514588A (en) 1994-12-13 1996-05-07 Exxon Research And Engineering Company Surfactant-nutrients for bioremediation of hydrocarbon contaminated soils and water
US5617436A (en) 1995-06-07 1997-04-01 Cornell Research Foundation, Inc. Strain-compensated multiple quantum well laser structures
US6030779A (en) 1995-07-18 2000-02-29 Diversa Corporation Screening for novel bioactivities
US6004788A (en) 1995-07-18 1999-12-21 Diversa Corporation Enzyme kits and libraries
US5958672A (en) 1995-07-18 1999-09-28 Diversa Corporation Protein activity screening of clones having DNA from uncultivated microorganisms
US6057103A (en) 1995-07-18 2000-05-02 Diversa Corporation Screening for novel bioactivities
US6168919B1 (en) 1996-07-17 2001-01-02 Diversa Corporation Screening methods for enzymes and enzyme kits
EP1213350A3 (en) 1995-08-11 2002-12-04 Novozymes A/S Method for preparing polypeptide variants by in vivo recombination
US5962258A (en) 1995-08-23 1999-10-05 Diversa Corporation Carboxymethyl cellulase fromthermotoga maritima
US5962283A (en) 1995-12-07 1999-10-05 Diversa Corporation Transminases and amnotransferases
US20030215798A1 (en) 1997-06-16 2003-11-20 Diversa Corporation High throughput fluorescence-based screening for novel enzymes
US5939250A (en) 1995-12-07 1999-08-17 Diversa Corporation Production of enzymes having desired activities by mutagenesis
US6238884B1 (en) 1995-12-07 2001-05-29 Diversa Corporation End selection in directed evolution
US6171820B1 (en) 1995-12-07 2001-01-09 Diversa Corporation Saturation mutagenesis in directed evolution
US5814473A (en) 1996-02-09 1998-09-29 Diversa Corporation Transaminases and aminotransferases
US5965408A (en) 1996-07-09 1999-10-12 Diversa Corporation Method of DNA reassembly by interrupting synthesis
US6489145B1 (en) 1996-07-09 2002-12-03 Diversa Corporation Method of DNA shuffling
US5830696A (en) 1996-12-05 1998-11-03 Diversa Corporation Directed evolution of thermophilic enzymes
DE69733059T2 (en) 1996-01-10 2006-03-02 Novozymes A/S METHOD FOR INVIVING THE PRODUCTION OF A MUTANT LIBRARY IN CELLS
US5942430A (en) 1996-02-16 1999-08-24 Diversa Corporation Esterases
US5958751A (en) 1996-03-08 1999-09-28 Diversa Corporation α-galactosidase
US6096548A (en) 1996-03-25 2000-08-01 Maxygen, Inc. Method for directing evolution of a virus
US5789228A (en) 1996-05-22 1998-08-04 Diversa Corporation Endoglucanases
US5877001A (en) 1996-06-17 1999-03-02 Diverso Corporation Amidase
US5763239A (en) 1996-06-18 1998-06-09 Diversa Corporation Production and use of normalized DNA libraries
ATE278416T1 (en) 1996-06-19 2004-10-15 Diversa Corp THERMOSTABLE PHOSPHATASES
US5939300A (en) 1996-07-03 1999-08-17 Diversa Corporation Catalases
WO1998013487A1 (en) 1996-09-27 1998-04-02 Maxygen, Inc. Methods for optimization of gene therapy by recursive sequence shuffling and selection
CA2268265A1 (en) 1996-09-27 1998-04-02 Maxygen, Inc. Methods for optimization of gene therapy by recursive sequence shuffling and selection
WO1998024799A1 (en) 1996-12-06 1998-06-11 Diversa Corporation Glycosidase enzymes
WO1998028416A1 (en) 1996-12-20 1998-07-02 Novo Nordisk A/S In vivo recombination
CA2276064C (en) 1997-01-17 2013-12-17 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
CA2281931A1 (en) 1997-02-13 1998-08-20 The Dow Chemical Company Recombinant haloaliphatic dehalogenases
CA2284097A1 (en) 1997-03-18 1998-09-24 Novo Nordisk A/S Shuffling of heterologous dna sequences
CA2284253A1 (en) 1997-03-18 1998-09-24 Jesper Vind An in vitro method for construction of a dna library
EP0996718B1 (en) 1997-03-18 2008-12-24 Novozymes A/S Method for constructing a library using dna shuffling
US6153410A (en) 1997-03-25 2000-11-28 California Institute Of Technology Recombination of polynucleotide sequences using random or defined primers
ZA983394B (en) 1997-04-22 1998-10-30 Gist Brocades Bv Process for the fermentative production of deacylated cephalosporins
US5948666A (en) 1997-08-06 1999-09-07 Diversa Corporation Isolation and identification of polymerases
US5876997A (en) 1997-08-13 1999-03-02 Diversa Corporation Phytase
US6610528B1 (en) 1997-08-26 2003-08-26 Diversa Corporation Microbial enrichment using a container having a plurality of solid support particles
AU1094699A (en) 1997-10-15 1999-05-03 Diversa Corporation Screening for novel compounds which regulate biological interactions
WO1999021979A1 (en) 1997-10-28 1999-05-06 Maxygen, Inc. Human papillomavirus vectors
AU1449499A (en) 1997-10-31 1999-05-24 Maxygen, Incorporated Modification of virus tropism and host range by viral genome shuffling
DK1036198T3 (en) 1997-12-08 2013-01-02 California Inst Of Techn Method for Preparation of Polynucleotide and Polypeptide Sequences
JP2002507393A (en) 1998-02-11 2002-03-12 マキシジェン， インコーポレイテッド Antigen library immunization
JP2002507392A (en) 1998-02-11 2002-03-12 マキシジェン， インコーポレイテッド Optimization of immunomodulatory properties of gene vaccines
MXPA00008352A (en) 1998-02-27 2002-10-17 Univ Pennsylvania Vaccines, immunotherapeutics and methods for using the same.
WO1999045154A1 (en) 1998-03-04 1999-09-10 Diversa Corporation Production and use of normalized dna libraries
BR9910174A (en) 1998-05-01 2001-03-06 Maxygen Inc Process for obtaining an optimized recombinant gene for pest resistance, library, and process for obtaining an organism that is pathogenic to a vegetable pest
KR20010052894A (en) 1998-06-17 2001-06-25 맥시겐, 인크. Method for producing polynucleotides with desired properties
AU3210200A (en) 1999-01-19 2000-08-01 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
AU3879300A (en) 1999-03-09 2000-09-28 Diversa Corporation End selection in directed evolution
WO2002000717A2 (en) 2000-06-23 2002-01-03 Maxygen, Inc. Novel co-stimulatory molecules
US20050154189A1 (en) 2000-06-23 2005-07-14 Maxygen Inc Novel co-stimulatory molecules

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999057271A2 (en) * 1998-05-01 1999-11-11 The Texas A&M University System Feline cd80, feline cd86, feline cd28, and feline ctla-4 nucleic acid and polypeptides

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
CHANG C-C J ET AL: "EVOLUTION OF A CYTOKINE USING DNA FAMILY SHUFFLING", NATURE BIOTECHNOLOGY, NATURE PUBLISHING, US, vol. 17, no. 8, August 1999 (1999-08-01), pages 793 - 797, XP000946490, ISSN: 1087-0156 *
CRAMERI A ET AL: "DNA SHUFFLING OF A FAMILY OF GENES FROM DIVERSE SPECIES ACCELERATESDIRECTED EVOLUTION", NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 391, 15 January 1998 (1998-01-15), pages 288 - 291, XP000775869, ISSN: 0028-0836 *
FARGEAS C A ET AL: "IDENTIFICATION OF RESIDUES IN THE V DOMAIN OF CD80 (B7-1) IMPLICATED IN FUNCTIONAL INTERACTIONS WITH CD28 AND CTLA4", JOURNAL OF EXPERIMENTAL MEDICINE, TOKYO, JP, vol. 182, no. 3, 1 September 1995 (1995-09-01), pages 667 - 675, XP002912153, ISSN: 0022-1007 *
GUO Y ET AL: "MUTATIONAL ANALYSIS AND AN ALTERNATIVELY SPLICED PRODUCT OF B7 DEFINES ITS CD28/CTLA4-BINDING SITE ON IMMUNOGLOBULIN C-LIKE DOMAIN", JOURNAL OF EXPERIMENTAL MEDICINE, TOKYO, JP, vol. 181, no. 4, 1 April 1995 (1995-04-01), pages 1345 - 1355, XP002018930, ISSN: 0022-1007 *
K.R. PARSONS ET AL: "Cloning of cattle CD80", IMMUNOGENETICS, vol. 49, 1999, pages 231 - 234, XP002231013 *
LAZETIC SASHA ET AL: "Chimeric co-stimulatory molecules that selectively act through CD28 or CTLA-4 on human T cells.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 277, no. 41, 11 October 2002 (2002-10-11), pages 38660 - 38668, XP002231015, ISSN: 0021-9258 *
PEACH R J ET AL: "BOTH EXTRACELLULAR IMMUNOGLOBIN-LIKE DOMAINS OF CD80 CONTAIN RESIDUES CRITICAL FOR BINDING T CELL SURFACE RECEPTORS CTLA-4 AND CD28", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 270, no. 36, 8 September 1995 (1995-09-08), pages 21181 - 21187, XP002912152, ISSN: 0021-9258 *
SSAN J. FAAS ET AL: "Primary structure and functional characterization of a soluble, alternatively spliced form of B7-1", JOURNAL OF IMMUNOLOGY, vol. 164, no. 12, 15 June 2000 (2000-06-15), pages 6340 - 6348, XP002231014 *
STEMMER W P C: "Rapid evolution of a protein in vitro by DNA shuffling", NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 370, 4 August 1994 (1994-08-04), pages 389 - 391, XP002082182, ISSN: 0028-0836 *

Also Published As

Publication number Publication date
US20060269566A1 (en) 2006-11-30
US20030190697A1 (en) 2003-10-09
JP2004513878A (en) 2004-05-13
US7094875B2 (en) 2006-08-22
AU2001272978A1 (en) 2002-01-08
EP1360290A2 (en) 2003-11-12
WO2002000717A9 (en) 2003-02-06
US7612170B2 (en) 2009-11-03
WO2002000717A2 (en) 2002-01-03
CA2411828A1 (en) 2002-01-03

Similar Documents

Publication Publication Date Title
WO2002000717A3 (en) Novel co-stimulatory molecules
WO2004029197A8 (en) Co-stimulatory molecules
AU4761100A (en) Methods and materials for generating sh3 domains with tailored binding properties
WO2001000244A3 (en) METHODS OF TREATMENT USING ANTI-ErbB ANTIBODY-MAYTANSINOID CONJUGATES
WO2003083041A3 (en) Cripto-specific antibodies
WO2001092581A8 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
MXPA03002413A (en) B7-like molecules and uses thereof.
WO2003018758A3 (en) Reagents and methods for smooth muscle therapies
WO2005123908A3 (en) Novel cancer cell lines and uses thereof
WO1995014089A3 (en) Cck-2, a receptor tyrosine kinase
AU2002303214A1 (en) Lps-responsive chs1/beige-like anchor gene and therapeutic applications thereof
WO2004035732A3 (en) Human polypeptides encoded by polynucleotides and methods of their use
AU8881201A (en) Tnf receptor-like molecules and uses thereof
AU2917697A (en) Dendritic cell receptor
WO1998059040A3 (en) Human catalytic telomerase sub-unit and its diagnostic and therapeutic use
IL158159A0 (en) NEW POLYNUCLEOTIDES AND POLYPEPTIDES OF THE IFNalpha-21 GENE
MXPA01011137A (en) Noninvasive genetic immunization, expression products therefrom, and uses thereof.
WO2000012535A3 (en) Neisseria meningitidis polypeptide, nucleic acid sequence and uses thereof
IL150115A (en) Isolated antibody that binds to rg1 polypeptides, an immunoconjugate comprising the isolated antibody and uses and methods associated therewith
WO1999065517A3 (en) Therapeutic compositions that produce an immune response by altering the antigen
WO1997011669A3 (en) MHC-class II restricted melanoma antigens and their use in therapeutic methods
WO2001059120A3 (en) Il-17 like molecules and uses thereof
WO2004096976A3 (en) Spex compositions and methods of use
WO2003044047A3 (en) Virulence proteins of the genus yersinia and uses thereof
WO2004031354A3 (en) Human sarcoma-associated antigens

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2411828

Country of ref document: CA

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2002 505839

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2001272978

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2001952193

Country of ref document: EP

COP Corrected version of pamphlet

Free format text: PAGES 1/38-38/38, DRAWINGS, REPLACED BY NEW PAGES 1/39-39/39; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2001952193

Country of ref document: EP